Feasibility of a Locally Shielded Brachytherapy Source by Arnold, John Richardson
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
May 2014
Feasibility of a Locally Shielded Brachytherapy
Source
John Richardson Arnold
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Arnold, J. R. (2014). Feasibility of a Locally Shielded Brachytherapy Source. Retrieved from https://digitalcommons.wpi.edu/mqp-all/
2038
 
 
 
 
 
Feasibility of a Locally Shielded Brachytherapy Source 
A Major Qualifying Project Report 
Submitted to the faculty 
Of the 
Worcester Polytechnic Institute 
In partial fulfillment of the requirements for the 
Degree of Bachelor of Science 
By 
 
John Richardson Arnold 
April 30, 2014 
 
 
 
 
 
Advisor: David Medich  
  
 
 
 
 
Abstract 
 
The feasibility of using Ytterbium 169 as a high dose rate brachytherapy source 
with local catheter shielding was investigated using Monte Carlo simulation 
software MCNP5.  The spectra of Yb-169 and Iridium 192 point sources were 
simulated through gold, platinum, and stainless steel 304 shields of varying 
thicknesses from .5-10 mm.  The simulation geometry was set up to conform to 
narrow beam detection geometry so the simulation results could be verified 
theoretically.  The Yb-169 spectrum was also simulated through a phantom of gold 
nanoparticle infused tissue to determine the feasibility of using infused tissue as a 
shield out of catheter.  The Yb-169 spectrum was effectively shielded by gold and 
platinum at .5 mm compared to Ir-192, while the gold nanoparticle infused tissue 
was ineffective as a shield.   
  
 
 
 
 
 
Introduction 
 
The American Cancer Society estimates that there were over 1.6 million new cases of 
cancer occurred in 2013, and that the cost of cancer diagnosis and treatment reached $201.5 
billion in 2008 
[1]
. The 5 year relative survival rate for cancer patients diagnosed between 2002 
and 2008 is only 68%, although survival statistics vary greatly by cancer type and stage at 
diagnosis 
[2]
. Treating cancer effectively is usually an invasive and costly process, often 
involving chemotherapy and/or surgery, but other treatment types are available. 
One effective method of cancer treatment is using radiation to destroy cancerous 
tissue.  In radiation therapy, there are two ways of treating a patient, through external beam 
therapy or through brachytherapy. In external beam therapy, a high energy x-ray beam is used 
externally to deliver precise and uniform radiation doses to the patient’s cancerous tissue while 
attempting to minimize radiation exposure to normal tissue.  In brachytherapy, radiation is 
delivered to the cancerous tissue by using small radioactive sources that are permanently 
implanted in the tumor, called low dose rate brachytherapy, or temporarily exposed to the tumor 
using a catheter, which is called high-dose rate brachytherapy. The advantage of brachytherapy 
over external beam radiation is that it provides a more localized radiation exposure which 
minimizes the quantity of normal tissue that is irradiated.  Brachytherapy sources (called seeds) 
can be implanted for a range of times and dose rates to deliver the appropriate dose for the 
patient being treated.  
Treating cancer with radiation will invariably lead to the irradiation of healthy 
tissue.  Radiation to healthy tissue can cause a number of negative side effects, including peeling 
 
 
 
 
and blistering of the skin, fatigue, and other side effects based on the location of the treatment 
[3]
.  Because the side effects of radiation are so severe, it is essential during treatment planning to 
minimize the dose to healthy tissue while still delivering the proper dose to the cancerous tissue. 
However, many commonly used brachytherapy sources, such as Iridium 192 or Cobalt 60, are 
too energetic to shield locally.   Finding a source useable for brachytherapy that can be 
effectively shielded locally would significantly increase the versatility of this treatment method. 
The goal of this Major Qualifying Project was to examine the effects of localized 
shielding on the emission spectrums of Ytterbium-169 and Iridium-192 through computer 
simulations and theoretical calculations.  The software used to simulate the shielding was Monte 
Carlo N-Particle 5 (MCNP5) created at Los Alamos National Laboratories and licensed through 
the U.S. Department of Energy.  
 
Background 
Radiation 
 Radiation, in general, is the release of energetic particles or waves by a source.  These 
particles and waves vary greatly depending on the sources they come from, and each type of 
radiation interacts with matter in ways we seek to understand.  Radiation can simply be 
understood as a means of energy transfer; it can provide electricity, cause harmful biological 
effects, and have other noticeable effects. 
 
Types of Radiation 
 There are a few ways to classify radiation, and not all types of radiation come from 
nuclear decay.  Gamma ray radiation comes from atomic nuclides, while x-ray radiation typically 
 
 
 
 
comes from a non-decaying source, such as a linear accelerator.  Gamma radiation and X-ray 
radiation are both emissions of light, and the range of energies that gamma and x ray photons can 
have is quite large.  Most linear accelerators can produce x-rays in the 6-20 MeV range, while 
gamma rays from nuclear decay can range from a few keV up to many MeV. 
 Atomic radiation that emits more than just a photon is called alpha or beta radiation.  
Alpha radiation occurs when a nuclide emits a Helium 4 nucleus, or two protons and two 
neutrons.  The nuclide loses 4 nucleons and two protons, so the end result is that the mass 
number is decreased by 4 and the atomic number is decreased by 2, changing the element of the 
decaying nuclide.  Beta decay occurs when the decaying nuclide emits either an electron or 
positron, resulting in beta minus or beta plus decay, respectively.  Beta minus decay causes the 
atomic number to increase by one, while beta plus decay causes the atomic number to decrease 
by one.  Beta decay in either form does not cause a change in the mass number of a nucleon. 
 
Attenuation and Shielding 
 When radiation interacts with matter, there are many possible outcomes.  Gamma 
radiation in particular can interact with matter in numerous ways.  Absorption occurs when a 
gamma ray interacts with an atomic electron, imparting some of its energy to the electron.  The 
electron, now in an excited state, could possibly then leave its atom and become a free electron, a 
process known as the photoelectric effect.  If the electron does not leave the atom, it remains in 
an excited state and can release a new photon, called coherent scattering.  Gamma radiation can 
also interact with particles in such a way as to change its wavelength and direction, which is 
called Compton scattering.   
 
 
 
 
 Because gamma radiation can interact with matter in a variety of ways, there are 
materials that can be used to block, or shield, radiation from targets that radiation could damage.  
The loss of intensity of radiation by interacting with matter is called attenuation.  Attenuation is 
dependent on the type of radiation, the material and its properties, and the intensity of the 
radiation.  These quantities are combined into the mass attenuation coefficient, µ, which is a 
measure of how effectively a substance absorbs or scatters light of a given wavelength, per unit 
mass.  Based on the thickness of the material d, and its density ρ, the probability that a photon 
will not interact in the material is 
         
The mass attenuation coefficient of elemental gold with respect to photon energy is shown in 
figure 1. 
  
Shielding Properties of Gold and 
Platinum 
 Due to the restrictions on 
shield placement for a brachytherapy 
geometry, we needed to find volume 
efficient shielding materials to test for 
the simulations.  Gold, platinum and 
stainless steel 304 make for excellent 
radiation shields under these volume restrictions.  They are biocompatible, or non-toxic when 
placed in the body in metallic form.  Gold and platinum are very dense; gold’s density is 19.3 
g/cm
3
 and platinum’s density is 21.45 g/cm3.  Stainless steel is not as dense, at 8 g/cm3, but the 
Figure 1 – The mass attenuation coefficient of elemental gold
[F1]
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cost difference of stainless steel from gold or platinum makes it worth investigating as well.  
Coupled with their relatively high mass-energy attenuation coefficients, these materials make 
very effective radiation shields.  Although gold and platinum are expensive, they are the best 
options for investigating implanted radiation shielding.   
 
Biological Effects Of Radiation 
 Through proof of evidence in a variety of experiments, it has been shown that the de 
facto best way to kill a cell clonogenically (preventing it from reproducing) is to damage its 
DNA.   DNA stores genetic information and is the blueprint for the types of proteins that get 
synthesized by the cell.  When powerful enough radiation interacts with DNA, it can ionize an 
atom or molecule in it, causing strand breaks that interfere with the DNA’s ability to do its job.   
 Ionizing radiation can interact with DNA in two ways.  When ionizing radiation imparts 
energy directly to the DNA molecule it is called a direct action.  Ionizing radiation can also 
interact with the matter around DNA, creating ions and free radicals that can interact with DNA 
and cause damage as well.  This is called an indirect action.  Water is one of the main channels 
of indirect action, with numerous interactions of ionized and excited molecules creating free 
radicals to interact with DNA.   
 Ionizing radiation’s ability to cause clonogenic cell death has many applications in 
medicine.  Ionizing radiation can be used in this way to treat cancer, or cells that divide 
uncontrollably.  Cancerous cells are abnormal in that they have no restrictions on how many 
times they divide and can cause adverse effects to people when there is a large enough mass of 
them.  Ionizing radiation, however, can clonogenically kill these immortal cells, preventing them 
 
 
 
 
from multiplying to the eventual death of the host.  Killing these tumors is a very effective way 
of treating this disease.   
 Radiation therapy is usually administered over an extended period of time, from a week 
to several months.  This happens because of the radioresistivity of hypoxic tumor cells.  When a 
tumor forms and grows it does not create capillaries and blood vessels.  As the tumor increases in 
size, blood will eventually be unable to reach the central cells of the tumor, causing them to 
become hypoxic, or oxygen deprived.  Because of the lack of oxygen, the number of indirect 
actions are reduced as the materials to form free radicals namely oxygen) is less abundant.  This 
noticeably increases the radioresistivity of the tumor cells, and thus makes treatment less 
effective.  Treating tumors over a series of irradiations will kill the outer, aerated cells and allow 
blood to flow the next layer of the tumor, aerating inner cells.  This process is repeated until the 
tumor eventually shrinks into nonexistence. 
 One method of radiation therapy is Brachytherapy, which will be discussed in detail. 
 
Brachytherapy 
 Brachytherapy is an advanced and cutting edge method of treating cancer.  In 
brachytherapy, short range radioactive sources (seeds) are placed into or near a tumor to give it a 
high dose of radiation while minimizing radiation to the surrounding healthy tissue.  
Brachytherapy seeds may be left in place for a variety of times, from minutes to the life of the 
source.  Brachytherapy seeds are encapsulated in a protective material to let the radiation escape 
and prevent any harmful chemical reactions that may happen between tissue and source.  There 
are currently two commonly used methods of brachytherapy: Low Dose Rate (LDR) and High 
Dose Rate (HDR) brachytherapy. 
 
 
 
 
 LDR brachytherapy uses low activity sources to treat cancer at early stages of 
progression.  In LDR brachytherapy, seeds the size of rice grains are implanted into the tumor 
using ultrasound guidance and insertion needles 
[1a]
.  These seeds are left in the tumor to irradiate 
the tumor over the following month or more, depending on the half-life and activity of the source 
used.  Once the seeds burn out they are usually left in the patient as they pose no health risk to 
the patient chemically or radiologically.  
LDR brachytherapy is commonly used to 
treat prostate cancer.  Figure 2 shows a 
common LDR brachytherapy setup for 
prostate cancer treatment.  
 HDR brachytherapy uses high 
activity sources to rapidly irradiate the tumor 
for shorter periods of time.  HDR sources are 
usually inserted into a tumor via one or more 
catheters and held in specific locations along the catheter(s) for specific amounts of time before 
being removed 
[2a]
.  Treatment is usually spread out over the course of 1-2 weeks, with the 
patient keeping the catheters imbedded until the treatment is complete.  After treatment is 
complete, the catheter(s) are removed and the patient has nothing left in his or her body.  HDR 
brachytherapy is a common and successful treatment for prostate, cervix, endometrium, breast, 
skin, bronchus, esophagus, and head and neck cancers as well as soft tissue sarcomas 
[3a]
. 
 Currently, HDR brachytherapy is unwieldy to use on tumors near vital organs because of 
the risk of side effects from irradiating the organ.  This MQP tested the feasibility of using gold 
and platinum as a shield for HDR brachytherapy to increase its versatility. 
Figure 2 – LDR brachytherapy seeds inside a prostate
[F2}
. 
 
 
 
 
 
Methods 
 
Simulation Setup and Considerations 
 The simulations performed for this Major Qualifying Project used the Monte Carlo N-
Particle 5 (MCNP5) radiation transport program created at Los Alamos National Labs and 
licensed through the Department of Energy. The two isotopes chosen were Yb-169 and Ir-192 
for their use as brachytherapy sources.  The shielding materials chosen were Gold, Platinum, and 
Stainless Steel 304, which were chosen due to their biocompatibility.   
 Simulations were run over a range of shield thicknesses to acquire transmission ratios for 
each shielding material and source combination geometry.  For these simulations the range of 
shielding thicknesses were selected based on the space available in the brachytherapy delivery 
catheter to enable localized shielding.  Sufficient particle histories were run to produce a 
convergence in the Monte Carlo code that is less than 5%. The isotopes were also simulated 
without shielding to acquire baseline flux values for each isotope.   
 
Simulated Shielding Geometry 
  The setup of the simulation geometry focused on the attenuation the shield will have for a 
simple, narrow beam geometry, as shown in figure 2.   The source used was an isotropic point 
Figure 3 – Narrow beam geometry the simulations and calculations were based on
[F3]
. 
 
 
 
 
source, which is a good approximation of a small source far away.  The shields used were 
cylinders of varying thickness (height), with the far plane 10 cm away from the source and the 
near plane varying distance between 9.95 cm and 9 cm from the source.  The detector, a sphere 
of 1 cm radius, was placed 10 cm from the back of the shield, or 20 cm from the source, to 
ensure that photons that the shield deflected were not detected. To collimate the simulations, a 
cylinder of radius 1.1 cm extended the length of the geometry and discounted any photons that 
passed through its surface.  The end result of the simulation was to obtain the number of photons 
that passed through the detector without regard to the photon’s energy or location where it 
passed through the detector. This photon flux was tracked by an F4 tally coded into the MCNP5 
distribution and called upon in the simulation code.  Once unshielded flux values and shielded 
flux values were acquired, the transmission ratio was calculated as the ratio of the photon fluence 
for the shielded and unshielded geometries via: 
              
             
              
 
An image of the geometry set up for these simulations is shown in figure 4.  
 
Testing the Validity 
of the Monte Carlo 
Simulations 
 
 The Monte 
Carlo code that generated the simulation data was developed to mimic a well-studied narrow 
beam geometry.  This geometry was used to validate the output data using its well behaved 
equations.  The transmission of the Yb-169 spectrum through gold and platinum using a “narrow 
Figure 4 – The geometry developed for the MCNP5 simulations 
 
 
 
 
beam” geometry was calculated using equation 8.43 from Atoms, Radiation and Radiation 
Protection by James Turner and compared to the data obtained through our simulations under 
similar geometry to test the validity of the simulation geometry 
[8]
.  The equation for calculating 
photon transmission through a shield in this geometry is 
              ∑   
       
 
 
Where µ (cm
2
/g) is the mass-energy attenuation coefficient of the material for photons of energy 
Ei, ρ is the density of the material (in 
g/cm
3
), d is the thickness of the 
material (in cm), and Ci is the yield of 
photons with energy Ei.  A histogram 
showing photon energies and yields for 
both isotope spectra are listed in figure 
5.  This equation was used along with 
data from NIST on the mass-energy attenuation coefficients, to calculate the theoretical values 
that the MCNP5 data should conform to. 
 
Gold Nanoparticles 
 Since gold is a very good radiation shield, we also explored other ways of using gold to 
shield radiation from an HDR brachytherapy source.  Gold nanoparticles (AuNP) were a 
possibility worth looking into, as functional nanoparticles are being researched for other medical 
purposes as well.  We tested the shielding effectiveness of AuNP infused into tissue.  To show a 
potential effect, we wanted to find the highest concentration of AuNP in tissue to make any 
Figure 5 – The spectra of Yb-169 and Ir-192 
 
 
 
 
differences in photon fluence more pronounced.  The highest concentration of AuNP found in 
the literature was 250 mM in vitro 
[7]
. Thus, the mass of gold in 1 cm
3
 of infused tissue is (with 
gold molar mass of 196.967 g/mol): 
         
               
 
        
    
 
           
            
 
With the amount of AuNP in the tissue found, we now solve for the mass ratio in tissue: 
       
 
   ⁄  
     
 
   ⁄
                           
Which leads to a tissue to solution ratio of 0.99745 : 1, or .4936 g Au per g tissue.  Using the 
NIST ICRU 4-component tissue, which has a density of 1.00 g/cm
3
, we can solve for the density 
of the infused tissue: 
                                    
   
         
 
   
 
These simulations were set up using the same narrow beam geometry as the previous 
simulations.  The transmission ratio was obtained by simulating the AuNP tissue and normal 
tissue at various thicknesses and using normal tissue rather than vacuum as the baseline 
transmission values.  The results from simulations of regular and infused tissue at the same 
thicknesses were compared to find the transmission reduction ratio that the infused gold 
nanoparticles caused: 
            
              
        
The Yb-169 spectrum was used for these AuNP simulations.  Yb-169 has a lower energy 
spectrum than Ir-192, so the reduction in photon fluence caused by the AuNP in the tissue would 
be more easily noticed than if Ir-192 was used.  
 
 
 
 
 
Results and Discussion 
 Figure 6 shows the results of the Iridium 192 simulations through gold, platinum, and 
stainless steel shields of varying thicknesses.  Gold and platinum effectively shielded 30% of the 
photons from the Iridium spectrum at 
.5 mm thickness, while stainless steel 
was found to be fairly ineffective at 
thicknesses appropriate for 
brachytherapy catheter shielding (on 
the order of .5 mm)
[9]
.  Iridium is one 
of the more commonly used 
brachytherapy sources, and the ability to 
shield 60% of photons at 1.5 mm could 
possibly be useful for Ir-192 
brachytherapy.  
 Figure 7 shows the results of 
the Ytterbium 169 simulations through 
gold, platinum, and stainless steel 
shields of varying thicknesses.  Unlike 
Ir-192, Yb-169 has a less energetic 
spectrum, so it is more effectively 
shielded by these materials, as shown in the graph.  At .5 mm, both gold and platinum shields 
reduced fluence by approximately 90%, which is very encouraging for using Yb-169 as a 
Figure 6 – Transmission of Ir-192 through Gold, Platinum, and Stainless 
Steel 
Figure 7 – Transmission of Yb-169 through Gold, Platinum, and 
Stainless Steel 
 
 
 
 
brachytherapy source with shielding.  
Figure 8 shows a comparison between the 
Ir-192 and Yb-169 fluence through gold 
shielding on a semilog scale.  The tenth 
value (10% transmission, or .1) for Yb-
169 occurs at .5 mm, while for Ir-192 it 
occurs at 5 mm, demonstrating how much 
more easily we can shield the Yb-169 
spectrum than the Ir-192 spectrum.  
Stainless steel also shielded 50% of the photons at 1 mm thickness, which is enough of a result to 
encourage experimental trials, given how inexpensive this material is with respect to gold and 
platinum.  
 Figure 9 shows the results of the gold nanoparticle infused tissue simulations.  At 
thicknesses of 1-10 mm, there was no 
significant difference between the regular 
ICRU 4-component tissue and the tissue 
infused with gold nanoparticles.  The 
simulations were done out to one inch 
(25.4 mm) of thickness of infused tissue, 
and at that thickness there was only a 5% 
reduction in the photon fluence of the Yb-
169 spectrum, which from our prior 
Figure 6 
Figure 8 – Transmission of Ir-192 and Yb-169 through Gold on a 
seimlog scale 
Figure 9 – Yb-169 transmission through gold nanoparticle infused 
tissue 
 
 
 
 
simulations is more easily shielded than the Ir-192 spectrum.  The conclusion from this series of 
simulations is that tissue infused with gold nanoparticles is not an effective shield for HDR 
brachytherapy purposes.  
 
Future Work 
 
 The Yb-169 results lead to a need for experimental verification.  If gold and platinum 
catheter platings reduce fluence by 90% in experimental trials, then using gold and platinum 
shielding in HDR brachytherapy could make this form of cancer treatment much more versatile 
and useful for treating tumors closer to vital organs.  The adaptation of Yb-169 as a commonly 
used brachytherapy source could also increase treatment versatility.  For the Master’s thesis 
portion of this project, a realistic geometry for Yb-169 in a shielded catheter will be developed 
for MCNP5 use, and dose distributions will be found using these simulations.  Measurements of 
Yb-169 via Gafchromic film may also be acquired. 
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